Savara (NASDAQ:SVRA) Shares Cross Above Fifty Day Moving Average - What's Next?

Savara logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Savara shares rose 10.4%, trading as high as $5.34 and closing at $5.21—above the 50-day moving average of $4.88.
  • Analysts give the stock a consensus “Moderate Buy” rating and an average price target of $10.29; six analysts rate it Buy and one rates it Sell.
  • Savara reported a quarterly loss of $0.17 per share, slightly better than analysts’ expected loss of $0.18 per share.
  • Interested in Savara? Here are five stocks we like better.

Savara Inc. (NASDAQ:SVRA - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $4.88 and traded as high as $5.34. Savara shares last traded at $5.21, with a volume of 12,260,866 shares changing hands.

Analysts Set New Price Targets

A number of analysts recently commented on the company. JPMorgan Chase & Co. initiated coverage on Savara in a research report on Wednesday, October 7th. They set an "overweight" rating and a $12.00 price target for the company. Royal Bank Of Canada set a $10.00 price objective on shares of Savara in a research report on Wednesday, October 7th. HC Wainwright started coverage on shares of Savara in a research note on Thursday, November 12th. They set a "buy" rating and a $10.00 price target for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a report on Thursday, October 15th. Finally, Wall Street Zen lowered Savara from a "hold" rating to a "sell" rating in a research note on Sunday, October 4th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.29.

Check Out Our Latest Analysis on SVRA

Savara Trading Up 10.4%

The company has a current ratio of 8.55, a quick ratio of 8.55 and a debt-to-equity ratio of 0.28. The stock has a fifty day moving average of $4.88 and a two-hundred day moving average of $5.32. The company has a market capitalization of $1.15 billion, a PE ratio of -8.54 and a beta of 0.32.

Savara (NASDAQ:SVRA - Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.01. As a group, sell-side analysts anticipate that Savara Inc. will post -0.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in Savara during the second quarter valued at $76,966,000. Nantahala Capital Management LLC boosted its stake in shares of Savara by 2.3% during the third quarter. Nantahala Capital Management LLC now owns 7,137,159 shares of the company's stock valued at $36,828,000 after purchasing an additional 160,349 shares during the period. Marshall Wace LLP boosted its stake in shares of Savara by 2.1% during the third quarter. Marshall Wace LLP now owns 6,386,775 shares of the company's stock valued at $32,956,000 after purchasing an additional 129,786 shares in the last quarter. Spruce Street Capital LP acquired a new stake in Savara in the 2nd quarter worth approximately $21,267,868. Finally, Nan Fung Trinity HK Ltd. grew its stake in Savara by 1,088.3% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company's stock valued at $9,507,000 after purchasing an additional 1,687,310 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

About Savara

(Get Free Report)

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara's lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Savara Right Now?

Before you consider Savara, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.

While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines